Managing Customs, Import/Export Requirements, And Cross-Border Logistics Challenges

By Shanker Ojha

In global biopharmaceutical clinical supply chains, cross-border logistics is frequently the most unpredictable operational bottleneck.^1,2 While cold chain technology has advanced significantly, technical packaging cannot protect a product if cargo remains stranded at a port of entry due to incomplete customs documentation, tariff misclassifications, or unaligned regulatory approvals.^2,3

Unlike commercial general cargo, investigational medicinal products (IMPs), human biological specimens, and advanced therapeutic medicinal products (ATMPs) carry strict stability windows.^1,5 A delay of 48 to 72 hours at a border point can lead to thermal packaging exhaustion, resulting in product degradation, unblinding risks, or complete trial discontinuation.^1,5

To mitigate these risks, biopharmaceutical sponsors and global trade operations must move away from reactive customs clearance routines. Instead, organizations must implement proactive, data-validated import and export frameworks that integrate regulatory change control directly into clinical supply chain planning.^2,3

Macro Data: Border Friction Points And Regulatory Vulnerabilities

Global distribution networks face systemic hurdles when moving temperature-sensitive biological goods across international borders.^1,2 Primary operational friction points include:

• Customs Valuation Discrepancies: Investigational drugs lack established commercial market values, often leading customs officials to question nominal invoice values. Inappropriate valuation assessments can trigger prolonged administrative holds or unexpected duty assessments.^2,3
• Import Licensing Delays: Many regulatory jurisdictions require trial-specific import permits prior to shipment dispatch. Dispatching cargo before receiving full regulatory clearance frequently results in quarantine at destination air hubs.^2,3
• Biological Material Clearance Protocols: Border authorities inspect biological shipments for biosecurity compliance, requiring detailed documentation regarding species origin, viral safety clearance, and non-contagious status.^1,6 Missing veterinary or biosafety certificates leads to immediate customs holds.^2,6
• Dual-Use Export Controls: Specialized bioprocessing equipment, high-grade bioreactors, and viral vectors can fall under international dual-use export control regimes, requiring specialized export licenses before leaving the country of origin.^3,6

High-Resilience Cross-Border Implementation Blueprint

Strategy A: Preclearance Validation And Digital Documentation Synchronization

Relying on physical paper invoices attached to shipping containers increases the risk of document loss or administrative errors at destination hubs.² Advanced trade logistics frameworks utilize electronic preclearance workflows.^2,3

• Digital Document Pre-Filing: Air waybills, pro-forma invoices, certificates of analysis (CoA), import licenses, and packing lists are transmitted digitally to local customs brokers prior to physical flight departure.^2,3
• Automated Tariff Classification: Utilizing standardized Harmonized System (HS) codes tailored specifically for biologics, clinical trial kits, and active pharmaceutical ingredients prevents reclassification holds by border officers.^2,3

Strategy B: Establish In-Country Regulatory Brokers And Importer Of Record (IOR) Networks

A primary reason for customs rejections is the lack of a legal entity to act as the Importer of Record (IOR) or Exporter of Record (EOR) in the destination country.²

• IOR/EOR Designation: Establishing clear legal agreements with local qualified entities ensures that tax liabilities, regulatory declarations, and customs queries are handled immediately upon cargo arrival.^2,3
• Customs Broker Integration: Partnering with specialized healthcare customs brokers ensures direct communication with airport border posts, enabling priority handling for temperature-sensitive air freight.²

Strategy C: Execute Route Risk Assessment And Border Delay Contingencies

Placing a clinical shipment into a cross-border transport lane without evaluating local customs clearance speeds introduces unnecessary quality risks.^1,2 Comprehensive logistics planning requires validated contingency procedures:^1,3

1. Pre-Shipment Documentation Audits: Quality assurance and trade compliance teams must review all shipping papers against destination country import guides prior to releasing cargo from the central depot.^2,3
2. On-Site Re-Icing Protocols: Establish preapproved service level agreements (SLAs) with airport ground handling stations to re-ice dry ice shippers or recharge phase-change materials if customs clearance exceeds 24 hours.^1,5

Cross-Border Operational Resilience Framework

To track import and export efficiency, prevent regulatory holds, and maintain inspection readiness, global supply chain teams should monitor key trade performance indicators.^2,3

Summary: Navigating Global Trade Complexity

Managing cross-border logistics for biopharmaceutical products requires strict operational discipline and advance regulatory alignment.^2,3 Protecting global supply lines requires three core principles:²

1. Synchronize Regulatory and Supply Operations: Ensure import licenses, clinical trial approvals, and customs documentation are fully aligned before executing physical shipments.^2,3
2. Standardize Digital Preclearance: Leverage electronic data interchange (EDI) to submit customs declarations prior to cargo departure, minimizing tarmac dwell times.²
3. Embed Local Contingencies: Partner with specialized healthcare brokers and airport ground services to provide immediate intervention, re-icing, and temperature-controlled storage during unexpected border delays.^1,2

By integrating proactive trade compliance, digital preclearance workflows, and robust local broker networks, biopharmaceutical companies can ensure seamless global product movement, protecting both clinical timelines and patient safety.^2,3

References:

1. World Health Organization. Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products. WHO Technical Report Series, No. 961, Annex 9, 2011.
2. European Commission. Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01). Official Journal of the European Union, 2013.
3. U.S. Food and Drug Administration. 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, 2025.
4. International Safe Transit Association. ISTA Standard 7D: Thermal Performance Testing for Packaging. ISTA Guidelines, 2023.
5. Parenteral Drug Association. Technical Report No. 39 (Revised 2021): Guidance for Temperature-Controlled Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products Through the Transportation Environment. PDA Journal of Pharmaceutical Science and Technology, 2021.
6. International Council for Harmonisation. ICH Topic Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. European Medicines Agency (EMA), 2022.

About The Author:

Shanker Ojha is a biopharmaceutical validation professional with over a decade of hands-on experience managing complex commissioning, qualification, and validation (CQV) cycles, QMS, and GMP compliance. His career is built on the shop floor, bridging the gap between technical engineering and time-sensitive manufacturing operations, including leading major process validation projects for biologics.

Having worked directly inside manufacturing hubs, Ojha knows firsthand how clinical supply lines stall when validation is treated as a retrospective paperwork drill. His focus is on synchronizing computer system validation (CSV) with physical assets and using risk-based frameworks to compress timelines. Shanker advocates for floor-level psychological safety, ensuring operators can flag technical anomalies instantly to resolve issues in real time.